A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519081-49-00

Acronym

CADPT17A12201

Enrollment

104

Registered

2025-09-22

Start date

2025-10-28

Completion date

Unknown

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to severe atopic dermatitis

Brief summary

Percentage change from baseline in the EASI score at Week 16

Detailed description

IGA response at Week 16: IGA score of 0 (clear) or 1 (almost clear) and at least 2 points reduction from baseline IGA response at Week 16, EASI-75 response at Week 16: ≥75% reduction (improvement) from baseline in EASI score response at Week 16, Treatment emergent adverse events, vital signs, ECG, and laboratory assessments

Interventions

DRUGPlacebo to GHZ339

DRUG-

DRUGGHZ339

DRUGTACROLIMUS

DRUGPIMECROLIMUS

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage change from baseline in the EASI score at Week 16	—

Secondary

Measure	Time frame
IGA response at Week 16: IGA score of 0 (clear) or 1 (almost clear) and at least 2 points reduction from baseline IGA response at Week 16, EASI-75 response at Week 16: ≥75% reduction (improvement) from baseline in EASI score response at Week 16, Treatment emergent adverse events, vital signs, ECG, and laboratory assessments	—

Countries

Czechia, France, Germany, Hungary, Italy, Netherlands, Poland, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026